Seraseq® Compromised FFPE Tumor DNA RM

Comprehensive genomic profiling (CGP) is an important part of an integrated clinical management of cancer patients, where cancer patients harboring variants/biomarkers of clinical utility are determined by highly multiplexed targeted NGS assay testing. Precise analysis of these patient samples requires high quality sample-to-result assay workflow controls to guide and validate the accurate identification of these actionable variants.

LGC SeraCare has developed a highly multiplexed Compromised FFPE Tumor DNA reference material imbibing “patient-like” characteristics to support end-to-end NGS workflows performed by clinical labs in the analysis of cancer patient samples. This product consists of 17 genes and 34 variants, incorporating all variant types – SNVs, INDELs, CNVs, and SVs. These variants were precisely quantitated by digital PCR and targeted NGS against a single well-characterized genomic background (GM24385).

• Highly multiplexed FFPE Tumor DNA reference material
• Contains 34 variants in 17 genes
• All variant types – SNVs (18), INDELs (10), CNVs (3) and SVs (3)
• For use in sample-to-result NGS workflows to analyze for mutation-positive variants in patient samples
• Manufactured in GMP-compliant ISO 13485 certified facility

*QIAamp FFPE Tissue DNA Kit

Solid Tumor FAQs

Review the common questions we receive from our customers and the responses we provide.

LEARN MORE